Innovation is Our History
CorneaGen delivers the highest quality donor tissue, unparalleled customer service and superior products that transform how ophthalmologists treat and care for every person impacted by corneal disease.
The EndoSerter-PL is just the latest example of CorneaGen advancing the next generation of corneal care.
Driving the Next Generation of Cornea Care
We were the first eye bank to process IEK tissue and the first to offer Amphotericin-B antifungal additive to corneal storage media. We introduced the Geuder Glass Cannula for DMEK, then pre-loaded the device. We invented the EndoSerter and developed Nano-Thin DSEK.
Our latest innovation is redefining DSEK: the EndoSerter-PL. Our patented EndoSerter DSEK insertion device, FDA-approved and now pre-loaded with Nano-Thin or Ultra-Thin DSEK.
Innovation is at the core of everything we do. Always innovating to help facilities, surgeons, and their patients.
Aurion Biotech - Cell Therapy for Corneal Endothelial Disease
CorneaGen established Aurion Biotech as an independent business unit of CorneaGen to drive focused development of cell therapy technology for endothelial disease. After early clinical research demonstrated safety, efficacy, and tolerability, Aurion Biotech raised more than $100M from outside investors and is currently driving the technology toward clinical trials and commercialization.
The separation of the two business units was the next logical step in both companies’ evolution, allowing each business the opportunity to focus on specific areas of need in corneal blindness and corneal disease and to continue innovating.